Clinical trial · Observational
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants
- description
- Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.
- interventionNames
- Other: No Intervention
Primary outcomes (2)
- measure
- Patients' Preference weights for different treatment attributes
- timeFrame
- Up to 1 day
- description
- Preference data will be collected via online survey questionnaires designed using DCE method.
- measure
- Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)
- timeFrame
- Up to 1 day
- description
- Preference data will be collected via online survey questionnaires designed using DCE method.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Physician inclusion criteria * The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice. * The physician has cared for at least ten nmHSPC patients in the past year. * The physician has experience prescribing NHT and ADT. Patient inclusion criteria * The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP. Exclusion Criteria: Physician exclusion criteria * None Patient exclusion criteria * The patient is castration resistant. * The patient has metastatic PC.
References
Publications (0)
Data not yet available